XENE
Xenon Pharmaceuticals Inc. Health Care Pharmaceutical Preparations Russell 3000
$37.41Close
$3.0BMarket cap
$33.49 – $70.9652-week range
Nov 2, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 10 · weaker than 90% of stocks over 12 months
- Far from its high 47% below its 52-week high
- Distribution down-day volume 1.9× up-day volume over 50 sessions
- Results soon Nov 2, 2026, in 1 day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
47%
1wk
up 5.9%
price change
1mo
up 0.6%
price change
12-month return
down 12%
market up 11% ·
its own down 22%
F-score
—
— Not assessed
Altman Z
31.24
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.1×
price / book
Earnings yield
down 13.4%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 52%
return on equity
Free cash margin
down 3732%
-$279.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
3.9%
$1.48 a day · 2×ATR $34.46
RS
10 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.53
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.7% over the year, from 76m to 80m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Sep 18, 2026-31% in one session16.7× volumeno filing matched-6% since
Financials
- Net -4612%
- Free cash -3732%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $32.2M | $18.4M | $9.4M | $0 | $0 | $7.5M |
| Operating income | -$31.3M | -$79.0M | -$129.1M | -$214.1M | -$279.3M | -$373.1M |
| Net income | -$28.8M | -$78.9M | -$125.4M | -$182.4M | -$234.3M | -$345.9M |
| Net margin | -90% | -428% | -1329% | — | — | -4612% |
| Earnings per share | -$0.83 | -$1.81 | -$2.07 | -$2.73 | -$3.01 | -$4.36 |
| Free cash flow | -$50.8M | -$71.6M | -$103.9M | -$156.7M | -$184.5M | -$279.9M |
| Free cash margin | -158% | -388% | -1102% | — | — | -3732% |
| Cash | $45.0M | $175.7M | $57.2M | $148.6M | $142.7M | $199.2M |
| Shareholders' equity | $171.4M | $550.0M | $721.5M | $927.9M | $754.9M | $581.8M |
| Shares outstanding | 35.01m | 51.63m | 62.59m | 75.37m | 76.42m | 80.01m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 3, 2025 | Quarterly ↗ | Sep 30, 2025 | 34d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results · Regulation FD ↗ |
| Jun 3, 2026 | Director or officer change · Shareholder vote ↗ |
| May 7, 2026 | Results · Regulation FD ↗ |
| Apr 13, 2026 | Director or officer change ↗ |
| Mar 13, 2026 | Other events ↗ |
| Mar 12, 2026 | Material agreement · Other events ↗ |
| Mar 9, 2026 | Regulation FD ↗ |
| Feb 27, 2026 | Other events ↗ |
| Feb 26, 2026 | Results · Regulation FD ↗ |
| Dec 1, 2025 | Director or officer change ↗ |
| Nov 3, 2025 | Results · Regulation FD ↗ |
| Oct 16, 2025 | Director or officer change ↗ |